Endothelin receptor antagonists as antihypertensives: the next frontier
| Autor: | Shawn D. Anderson, Benjamin J Epstein |
|---|---|
| Rok vydání: | 2009 |
| Předmět: |
Endothelin Receptor Antagonists
medicine.medical_specialty Drug Evaluation Preclinical Renal function Blood Pressure Disease Pharmacology Internal medicine Internal Medicine medicine Animals Humans Antihypertensive Agents Clinical Trials as Topic Proteinuria business.industry Endothelin receptor antagonist General Medicine medicine.disease Endocrinology Blood pressure Cardiovascular Diseases Heart failure Pathophysiology of hypertension Hypertension Endothelium Vascular medicine.symptom Cardiology and Cardiovascular Medicine Endothelin receptor business |
| Zdroj: | Expert Review of Cardiovascular Therapy. 7:675-687 |
| ISSN: | 1744-8344 1477-9072 |
| DOI: | 10.1586/erc.09.24 |
| Popis: | The endothelin system is a pivotal player along the continuum of cardiovascular disease. There is convincing evidence that the system not only exerts a potent pressor effect but also promotes end-organ damage independent from blood pressure changes. The role of endothelin receptor antagonists (ERAs) in the treatment of hypertension is rapidly evolving. Recent studies demonstrate a formidable antihypertensive effect. Utility of ERAs is likely to be greatest in patients with resistant hypertension. Beyond blood pressure lowering, ERAs exert several properties that may confer additional protection, including effects on endothelial function, atherosclerosis, arterial stiffening, renal function and proteinuria. The full potential of this class will only be realized when the results of ongoing and future studies in hypertension, heart failure and other forms of cardiovascular disease are completed. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|